iiinova — where your digital self keeps evolving

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/09/2026

📢 Have experience with clinical trials and PPI? Join the STAMPEDE3 PPI Group to help shape a prostate cancer trial exploring personalised treatment approaches. We're looking for men with lived experience of prostate cancer. ✍️ Apply by 30 Sept by emailing mrcctu.ppiadvice@ucl.ac.uk.

001

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 23/09/2026

Working in clinical trials and want to understand the meanings of common statistical terms used in clinical trials? Join our 4-day course to learn what’s important and why, and gain an understanding of statistical methods and analyses. 📅 2-5 Nov 2026 🔗 bit.ly/4c7zKyN

Poster, it reads "An introduction to design and analysis of clinical trials: statistics for non-statisticians
2-5 November 2026
9:30-12:45 (UK time)
Online via Zoom
More info/registration - QR code

021

Reposted by UCL Innovative Clinical Trials Unit

MS Society UK @mssocietyuk.bsky.social · 17/09/2026

We’re excited to announce the interim results of our Octopus trial. Octopus is a multi-stage, multi-arm clinical trial, transforming the way we test treatments for progressive MS. 🔬 Professor Jeremy Chataway, chief investigator, shares the interim results. Read more: mssoc.uk/3TyjTmA

011

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 22/09/2026

This #UrologicalCancerAwarenessMonth, learn about #STAMPEDE2, a trial investigating whether SABR (targeted radiotherapy) and 177Lu-PSMA-617 (nuclear medicine) can improve outcomes for people with advanced prostate cancer when added to standard care. 🔗More about STAMPEDE2: buff.ly/kiFkZ1w

innovative-ctu.ucl.ac.uk

STAMPEDE2 | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/09/2026

Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks, rather than in the form of daily tablets, according to results from the LATA trial www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

HIV injections work better than tablets for young people | UCL Innovative Clinical Trials Unit

012

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 17/09/2026

🚨 Exciting interim results from the OCTOPUS trial! Alpha-lipoic acid shows early promise in slowing progression of MS and will move to the next stage of the trial. A milestone for innovative #MAMS trials in MS. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st... @mssocietyuk.bsky.social

innovative-ctu.ucl.ac.uk

Alpha-lipoic acid shows ‘early promise’ to treat progressive multiple sclerosis | UCL Innovative Clinical Trials Unit

112

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 15/09/2026

If you're at #ICTMC2026 this week, make sure to check out the Data-enabled trials session featuring researchers from the Transforming Data for Trials team. 🗓️ Wed 16 Sep, 3:45- 5 PM 📍 Hall 9 🔗 inconference.eventsair.com/ictmc-2026 #ClinicalTrials #ICTMC2026 #HDRUK #TDfT

inconference.eventsair.com

ICTMC 2026, ICC BIrmingham - ICTMC 2026 - ICC Birmingham

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 14/09/2026

📢 Attending #ICTMC2026? Don't miss the keynote from Matt Sydes (mattsydes.bsky.social), Honorary Prof. of Clinical Trials & Methodology. 🗣️ "Bringing new treatments to patients: improving clinical trials with healthcare systems data" 🗓️ 16 Sept, 11:30–12:30, Hall 1 🔗 buff.ly/hYjovbd #TDfT #HDRUK

inconference.eventsair.com

ICTMC 2026, ICC BIrmingham - ICTMC 2026 - ICC Birmingham

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 10/09/2026

📢 Heading to Birmingham for #ICTMC2026? Our #ClinicalTrials methodology researchers will be presenting talks, posters and workshops throughout the conference. 🔗 View the full schedule and find out where to meet the team: www.innovative-ctu.ucl.ac.uk/news/news-st...

$Innovative Clinical Trials Unit at ICTMC 2026 Oral presentations Tuesday 15 September Missing data and infographics. 10:45-12PM (BST). Missing viral load measurments in HIV treatment trials: a comparison of approaches (Tra My Pham) Wednesday 16 September Conduct- Data-enabled trials. 3:45-5PM (BST). Streamlining event ascertainment from health systems data: accuracy of the SCORE-CVD myocardial infraction phenotyping algorithm in a prostate cancer trial (Sharon Love, Macey Murray) 3:45-5PM (BST). Health systems data for evaluating mortality outcomes in randomised prostate cancer trials: A data utility comparison study within the STAMPEDE and PATCH trials (Grisma Patel) Conduct-Trial management, trial monitoring and quality control. 3:45-5PM (BST). Smarter Processes for Enhanced Clinical TRial Efficiency (SPECTRE): Identifying Inefficiencies in site set-up (Aaron horsey) Analysis - Borrowing of information. 1:45-2:45PM (BST). A comparison of different information-borrowing approaches in a trial evaluating dolutegravir-based antiretroviral therapy in HIV-infected children (Wenyue Li)$

Innovative Clinical Trials Unit at ICTMC 2026
Oral presentations
Thursday 17 September
Design-Adaptive and innovative designs. 10:40-11:40AM (BST): Recommendation-wise type 1 error: a new measure for clinical trials using Bayesian borrowing for precision medicine (Ian White)
Analysis-Data-enabled trials and secondary data. 10:40-11:40AM (BST). The need for fully effective federated analytics of data sources of clinical trials (Stella Fabiane)

Innovative Clinical Trials Unit at ICTMC 2026
Posters
COSSMaT Study- Core Outcome Set for Severe Malaria Treatment Trials - Gideon Asamoah
From Paperwork to Partnership: A Collaborative and Risk-Proportionate Approach to Trial Database Development - Lindsey Masters
Emulating a randomised controlled trial based on the ODYSSEY trial design using paediatric HIV cohort data - Jerome Johnson
Measurement and reporting of menstrual blood loss outcomes in clinical trials which assess heavy menstrual bleeding: a comprehensive review - Lily Nicholson
Understanding the current state of knowledge around using Health Systems Data in clinical trials - Macey Murray
Assessing the utility of routinely collected Health Systems Data and Case Report Form data in Randomised Controlled Trials: A Systematic Review of DUCkS - Grisma Patel
Evidence‑Informed Consent Guidance for Trustworthy Access to Health Systems Data for Trials (CrossWord): Insights from a multistakeholder collaborative approach - Kate Roberts

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 07/09/2026

As we mark #WorldRadiotherapyAwarenessDay, new findings from the ARCHERY study highlight the potential of AI to expand access to high-quality radiotherapy planning in low- and middle-income countries. 🔗Read more about the results: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

AI tool for radiotherapy can support the global effort to eliminate cervical cancer | UCL Innovative Clinical Trials Unit

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/09/2026

September is #GynaecologicalCancerAwarenessMonth, and we're highlighting the ICON8B trial. The study found that women with advanced #OvarianCancer lived longer when chemotherapy was given weekly alongside bevacizumab, compared with the standard treatment every 3 weeks. 🔗Read more: buff.ly/QyYtc9S

innovative-ctu.ucl.ac.uk

Weekly chemotherapy with bevacizumab improves ovarian cancer survival compared to having it once every three weeks | UCL Innovative Clinical Trials Unit

20 Oct 2025

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/08/2026

📢 We're hiring! We are looking for a Science Communications Officer (maternity cover). A varied role creating content that showcases the impact of national & international trials in cancer, Parkinson's disease, paediatric HIV, multiple sclerosis & more. 📅 Apply by 10 Sept 2026 🔗 buff.ly/sdYteSn

ucl.ac.uk

UCL – University College London

UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

011

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 11/08/2026

Working in clinical trials and want to make better use of routinely collected healthcare data? Learn how to compare datasets and assess their suitability for specific research questions at our upcoming DUCks workshop. 📅 22 Oct 2026, 10-1 (UK time) 🔗 More information: bit.ly/3RHiUQf

Flyer DUCkS workshop
Thur 22 October 2026
10-1 (UK time)
In person - 90 High Holborn, London
More info/registration: QR code

002

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 29/07/2026

🚨 Exciting results from the LATA trial at #AIDS2026! LATA showed that having injections every 8 weeks was better at keeping HIV under control than taking daily tablets for young people living with HIV. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st... aidsconference.bsky.social

Infographic with LATA results. It reads:
LATA tested long-acting injectable cabotegravir and rilpivirine (CAB/RPV), given once every eight weeks, compared to daily TLD (tenofovir disoproxil, lamivudine and dolutegravir) tablets.
476 young people living with HIV in Sub-Saharan Africa
• 12-19 years old
• Already on treatment for ≥ 1 year
• HIV undetectable for ≥ 1 year
• No previous treatment failure
• Enrolled in Uganda, Kenya, Zimbabwe and South Africa
They were randomly allocated to one of these 2 groups:
Injections every 8 weeks
Daily tablets
Are long-acting injectables effective?
Proportion of young people with 2 consecutive viral loads ≥50 copies/mL by 96 weeks:
• Injections: 1%
• Daily tablets: 6%
Long-acting injectables were more effective than daily oral TLD tablets.
Are long-acting injectables safe?
• No differences in safety between groups
• Most people in the long-acting injectables group had mild injection-site reactions, usually pain, which quickly resolved.
What did young people think of long-acting injectables?
94% of people in the long-acting injectables group said it was a lot easier than taking daily medicines.
Conclusion: Long-acting injectable cabotegravir/rilpivirine are a highly effective and acceptable treatment option for young people living with HIV.
Logos: Innovative Clinical Trials Unit, Johnson & Johnson, EDCPT
LATA is funded by the European Developing Countries Clinical Trials Partnership (EDCTP) (grant number RIA2017MC-2005) and funding from Janssen Pharmaceutica NV.

012

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 28/07/2026

📢 Interested in health economics in clinical trials? Don't miss the upcoming webinar from the InCTU Capacity Strengthening Hub on "How to be a Good Trial Health Economist." 📅 30 July | 10:00 AM BST Link to register 👇

001

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 24/07/2026

🆕 New publication alert! Results from the PediCAP trial show that children recovering from severe pneumonia can safely switch from injectable to oral antibiotics earlier, allowing them to come home from hospital sooner. @thelancet.com 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

Children with severe pneumonia could leave hospital sooner with oral antibiotics | UCL Innovative Clinical Trials Unit

120

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 21/07/2026

Are you attending #AIDS2026? Don't miss the latest findings from our #HIV trials! Check out the list of talks & posters from the Innovative Clinical Trials Unit researchers and our partners: www.innovative-ctu.ucl.ac.uk/news/news-st... @iasociety.bsky.social

innovative Clinical Trials Unit at the AIDS 2026 Conference
Oral presentations:
Wednesday 29 July, 10:30AM (BRT): AIDS 2026-Co-chair's choice: "LATA 96-week results" (Mutsa Bwakura Dangarembizi)
Thursday 30 July, 10:30 AM (BRT): Ageing with HIV: Live long, live strong: "The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study" (Ruolan Wang)

Innovative Clinical Trials Unit at the International Workshop on Pediatrics & HIV 2026
Posters
Predictors of viral non-suppression in children living with HIV initiating second-line antiretroviral therapy in the ODYSSEY and CHAPAS-4 trials (Pauline Amug)
HIV-1 resistance in children aged 2 to <15 years receiving DTG/3TC or DTG+2NRTI: results from the D3/PENTA-21 trial over 96 weeks (Johannes C Botha)
Prevalence of renal impairment in children and young adults living with HIV in Europe and Thailand (John O’Rourke)
T-Cell Subsets, T-Cell Receptor Repertoire and HIV-1 Virological Reservoir in Children Initiating First-Line Dolutegravir versus Standard-Of-Care ART: Results from the ODYSSEY Trial (Matt Byott (on behalf of Kathleen Gartner))

013

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 20/07/2026

A major milestone for GARDP's #NeoSep1 trial 🎉 The first baby has now been enrolled in Vietnam, continuing the expansion of this landmark neonatal sepsis trial from Africa into Asia.

112

Reposted by UCL Innovative Clinical Trials Unit

GESIS Training @gesistraining.bsky.social · 16/07/2026

Join our #GESISworkshop with @matteoq21.bsky.social & Tra My Pham (@innovative-ctu.bsky.social) to learn how to create, analyze, and report simulations in R/Stata. Discover when methods shine or fail, uncover their hidden biases, and compare alternatives. Registration ➡️ t1p.de/simulation_s...

GESIS Workshop
Using Simulation Studies to Evaluate Statistical Methods
19 - 20 & 26 - 27 November
Matteo Quartagno & Tra My Pham (both UCL)

012

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 16/07/2026

📢 Call for Digital Outcome Measures proposals for the AD-SMART trial The trial team is looking for validated, patient-friendly digital tools for AD-SMART, a trial accelerating the search for better and safer Alzheimer’s treatments. 🔗 More info: www.innovative-ctu.ucl.ac.uk/studies/all-...

innovative-ctu.ucl.ac.uk

AD-SMART call | UCL Innovative Clinical Trials Unit

001

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 06/07/2026

Every year, millions of newborns develop sepsis. For many, the antibiotics available are no longer effective. We're proud to announce the launch of the #NeoSep1 clinical trial at Aga Khan University Hospital in Pakistan, helping advance better treatment options for newborns with sepsis. #AMR

122

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 30/06/2026

🎧 New Trial Talk podcast! The ACORD collaboration is bringing together experts across disciplines to transform clinical trials for neurodegenerative diseases. Hear from James Carpenter and Ed Jabbari about the vision & impact of this collaboration 👉 soundcloud.com/trial-talk-p...

soundcloud.com

The ACORD collaboration: Innovative Clinical Trials for Neurodegenerative Diseases

ACORD is a pioneering collaboration that brings together experts from a wide range of disciplines to accelerate the development of treatments for neurodegenerative diseases. In this episode, we explor

010

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 24/06/2026

🚨 This is BIG! 👶JIPMER in India enrolled the first baby in Asia into the NeoSep1 trial. Since then, babies have been enrolled at the Rohtak site, with Mumbai next. 🧪 Led by GARDP and partners, NeoSep1 is one of the most ambitious clinical trials ever undertaken for neonatal sepsis.

143

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/06/2026

🚨New results from the SNAP trial! Researchers have identified the optimal antibiotics for staph blood infection, a serious global health issue. A thread 🧵👇

222

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 04/06/2026

🚨 New publication alert! Results from the SMAART-CHARISMA study show that artesunate (the standard treatment for severe malaria in children) remains effective, even in regions where drug resistance is rising in Africa. 🔗 Read more: www.imperial.ac.uk/news/article...

imperial.ac.uk

Standard malaria treatment still the best, even against resistant strains

Artesunate – the standard treatment for severe malaria in children – is still effective, even in regions of Africa where drug-resistant m...

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 02/06/2026

📈 News from the RAMPART trial! Results presented at #ASCO26 show that using the immunotherapy drug durvalumab alone does not lower the risk of kidney cancer coming back after surgery compared with active monitoring. 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

Using two immunotherapy drugs together benefits people with kidney cancer | UCL Innovative Clinical Trials Unit

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/06/2026

We are excited to announce the launch of REFINE-MS! A new clinical trial for people living with relapsing-remitting MS, exploring whether treatment can be taken less often while still keeping disease activity under control. 🔗 Find out more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

A new trial for people living with relapsing-remitting multiple sclerosis launches in the UK | UCL Innovative Clinical Trials Unit

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 28/05/2026

Heading to #ASCO26? Don’t miss James Larkin presenting new RAMPART results on whether 1 or 2 immunotherapy drugs can reduce kidney cancer recurrence vs active monitoring. 📆 30 May, 8:36–8:48 AM CDT 📍Clinical Science Symposium 🔗More about RAMPART: www.innovative-ctu.ucl.ac.uk/studies/all-...

innovative-ctu.ucl.ac.uk

RAMPART | UCL Innovative Clinical Trials Unit

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 20/05/2026

Today is #InternationalClinicalTrialsDay 🌍 Patients and the public are at the heart of our research. Our #PPI group helps shape our trials, making them better, more relevant, and more inclusive. Today we’re asking our patient reps: What are you #ProudestOf in your work as part of the PPI group?

A quote from Ben, it reads "I am proud of the work our PPI group has done in providing training and support to new PPI representatives and researchers, helping to maximise the impact of PPI in every study. The rapid and innovative response to the need for PPI in COVID research, by developing the concept of a PPI panel, is another great achievement that is now being applied in other disease areas, such as TB."

A quote from Danielle, it reads "I am proudest of my involvement in promoting the use of the patient information sheet (PIS) developed by Dr Peter Knapp, ever since it was first presented at the INVOLVE conference. As a founder member of the Paediatric Oncology Reference Team (PORT), I made sure we adopted it for paediatric oncology trials. This made a significant difference for PORT, as we could make the PIS much more accessible. This is especially important with some children’s cancers, where Day 1 randomisation means families have very little time to get their head around things before making a decision for their child."

A quote from Ian, it reads "I am proud of our contribution to the success of clinical trials through our provision of advice for the Quality Management Advisory Group. We know it has made a positive difference to the studies in the eyes of the project PPI leads, who feel the review of documents has been excellent. The comments we provide prompt interesting discussions within the trial teams, leading to improvements in PPI processes."

A quote from Virginia, it reads "I’m proudest of the contribution we make to helping studies become easier for everyone to read and understand. Through PPI, we also encourage researchers to think about the real, practical realities of running a study and how best to involve participants. That’s where we really see the difference we make!"

272

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 18/05/2026

📈 New results from ARCHERY at #ESTRO26 The ARCHERY AI radiotherapy planning tool is effective in delivering timely and high-quality radiotherapy for the treatment of cervical cancer, contributing to the global effort to eliminate cervical cancer worldwide. 🔗 Read more:

buff.ly

AI tool for radiotherapy can support the global effort to eliminate cervical cancer | UCL Innovative Clinical Trials Unit

18 May 2026

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 15/05/2026

Heading to #ESTRO26? Don’t miss Ajay Aggarwal presenting the first results from ARCHERY: a global trial evaluating AI-based radiotherapy treatment. 📅 18 May 2026 ⏰ 14:10 (CEST) 📍 A1 Plenary ”Highlights: Latest trials.” 🔗More about ARCHERY: archery.mrcctu.ucl.ac.uk

archery.mrcctu.ucl.ac.uk

Home | ARCHERY

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 13/05/2026

It’s Wednesday, and we’re back with another #ProudestOf moment from the Unit! This week, we’re spotlighting Andy Sum, a brilliant member of the Data Management Systems team at the Unit. Andy shared what he’s #ProudestOf in his work at the Unit 👇

A card with a quote from Andy. It reads “I am proud to contribute to the development of our trial websites, ensuring consistency in design and layout, and seamlessly integrating our branding and logos. It’s satisfying to know that this technical foundation helps present our trials in a professional way, making it straightforward for people to navigate and find the information they need.”

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 06/05/2026

Midweek already? Let’s celebrate another #ProudestOf moment from our brilliant team at the Unit! This week, we’re spotlighting Alex Green, one of our dedicated Clinical Trial Managers working on paediatric HIV. Alex shared what she’s #ProudestOf in her work at the Unit 👇

A card with a quote from Alex. It reads “I am proud to have contributed to improving data quality across three paediatric HIV studies (BREATHER Plus, LATA and D3), ultimately helping to enhance the lives of young people living with HIV. I have played a key role in the development of monitoring processes and tools to improve their efficiency, while increasing confidence that our data are accurate and reliable. I have also delivered training for local monitors in Uganda, contributing to capacity building and strengthening sustainable research practices.”

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 30/04/2026

🆕 New publication! A new analysis from the STAMPEDE trial shows that a routine blood test can provide valuable insight into survival in advanced prostate cancer. thelancetoncol.bsky.social 🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...

innovative-ctu.ucl.ac.uk

A routine blood test offers new insight into survival in advanced prostate cancer | UCL Innovative Clinical Trials Unit

010

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 29/04/2026

It’s Wednesday, which means we’re back with another #ProudestOf moment from the Unit! This week, we’re delighted to celebrate Angela Meade, who stepped into her new role as Director of the Innovative Clinical Trials Unit in April. Angela has shared what she’s #ProudestOf in her work at the Unit 👇

A card with a quote from Angela. It reads “I’m proudest of the impact our clinical trials have had in improving health outcomes, and of seeing meaningful, collaborative research make a real difference. A major highlight of my career has been leading UCL’s MSc in Clinical Trials. Creating the programme and interacting with students has been energising; building skills, confidence and ambition for high quality research through lively interaction and fresh perspectives. I feel fortunate to work with generous, talented colleagues across disciplines and countries, united by a shared commitment to improving health. I’m especially proud to be leading the UCL Innovative CTU as we work together to deliver smarter studies, global impact and better health.”

030

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 22/04/2026

It’s Wednesday, and we’re back with another #ProudestOf moment from the Unit! This week, we’re spotlighting Lindsey Masters (lkmasters.bsky.social), Head of Data Management Systems at the Unit. We asked Lindsey what she’s #ProudestOf from the Unit’s work. Here’s what she shared 👇

A card with a quote from Lindsey. It reads “I'm proud that the unit is recognised as a leader in the development of complex and innovative trial designs, and in the operational expertise required to implement them successfully, leading to real improvements in healthcare both in the UK and around the world.”

030

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 20/04/2026

"Practical use of multiple imputation to handle missing data in Stata" short course The programme combines clear explanations of assumptions and limitations with hands‑on exercises and real examples. 📅 1-2 June 2026 📍 Innovative Clinical Trials Unit, 90 High Holborn www.ucl.ac.uk/population-h...

ucl.ac.uk

001

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 20/04/2026

🆕 New publication! Our researchers explored how #Bayesian methods are used in confirmatory #ClinicalTrials. The most common reasons for choosing Bayesian methods were making probability statements about the interventions or the flexibility to adapt the trial design. 🔗 Read more: buff.ly/wHnFcuC

journals.sagepub.com

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

021

Reposted by UCL Innovative Clinical Trials Unit

Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 15/04/2026

🚨 A significant step forward in newborn health GARDP’s #NeoSep1 trial has started in Ghana.

133

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 13/04/2026

💻 Short course: Using Simulation Studies to Evaluate Statistical Methods A comprehensive introduction to designing, coding, analysing and interpreting simulation studies in statistical research. 📅 14–17 May 2024 ⏰ 2-5 PM (UK time) 📍 Online (Zoom) 🔗 More info: www.ucl.ac.uk/population-h...

ucl.ac.uk

Using simulation studies to evaluate statistical methods

Next Course: 9th - 12th June 2026 Timings: 14:00 - 17:00 (UK Time) Location: via Zoom

011

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 08/04/2026

📰 Hot off the press - the BREATHER+ results came out yesterday in The Lancet HIV! The trial found that taking HIV medicines every day, without breaks, remains the most effective way to keep the virus under control in young people living with #HIV. 🔗 Read the full story: buff.ly/Xnf8kCu

innovative-ctu.ucl.ac.uk

Young people living with HIV should take their HIV medicines daily, according to the BREATHER+ trial | UCL Innovative Clinical Trials Unit

08 Apr 2026

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 07/04/2026

This #WorldHealthDay, we celebrate the theme “Together for health. Stand with science.” Explore our Capacity Strengthening Hub, a collection of free resources to build clinical trial skills and support high-quality research worldwide. 🔗

buff.ly

Welcome to the MRC Clinical Trials Unit (MRC CTU) at UCL Capacity Strengthening Hub • MRC Clinical Trials Unit at UCL

Find out what The Global Health Network can do for you. Register now.

000

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/04/2026

It’s Wednesday, and we’re back with another #ProudestOf moment from the Unit! This week, we celebrate Jemima Thomson, Research Fellow and proud member of the ICTM Education team. We asked Jem what she’s #ProudestOf in her work at the Unit. Here’s what she shared 👇

A card with a quote from Jem. It reads “The thing I’m proudest of about the unit’s work is the dedication and hard work that goes into innovation and improving how clinical trials are conducted. Striving to make trial conduct more efficient benefits everyone, especially trial participants and patients who may benefit from treatments in the future. In my own work, I am most proud of my contribution to education. The students we teach are the trialists of the future. I think that having the opportunity to learn from specialists in the field is inspiring. I am always learning!”

121

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 01/04/2026

📢 Big news for our Unit! From today, the MRC Clinical Trials Unit at UCL becomes the UCL Innovative Clinical Trials Unit. Our name is changing, but our mission isn’t. We will continue to deliver smarter studies, global impact, better health. 🔗 www.innovative-ctu.ucl.ac.uk

innovative-ctu.ucl.ac.uk

Home | UCL Innovative Clinical Trials Unit

050

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 26/03/2026

March is #ProstateCancerAwarenessMonth, and we are excited to share new results showing that hormone patches are as good as injections at controlling locally advanced prostate cancer, with fewer side effects. 🔗 Read the full story: www.mrcctu.ucl.ac.uk/news/news-st...

mrcctu.ucl.ac.uk

Hormone patches are as effective as injections for treating non-metastatic prostate cancer | MRC Clinical Trials Unit at UCL

110

Reposted by UCL Innovative Clinical Trials Unit

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 25/03/2026

📣 Join a qualitative interview study on treatment decisions in metastatic hormone sensitive prostate cancer. Seeking medical and clinical oncologists, urologists, and prostate cancer nurse specialists. More details + sign up ➡️ buff.ly/q3iFHCm @annabellesouth.bsky.social @mrcctu.bsky.social

Are you a health professional who treats people with prostate cancer in the UK? Your views will help us understand what influences how people with metastatic hormone-sensitive prostate cancer are treated. We are interested in the perspectives of healthcare professionals such as medical and clinical oncologists, urologists, and prostate cancer nurse specialists. Help us improve communication and treatment for prostate cancer. Participation includes: a 30-60 minute online interview via Microsoft Teams, no prior knowledge required, no payment offered. Scan the QR code or visit the provided link to take part. Contact Annabelle South for more information. Sponsored by the STAMPEDE trial, coordinated by MRC Clinical Trials Unit at UCL.

021

UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 25/03/2026

It’s time for another #ProudestOf Wednesday! This week we’re celebrating Lou Brown, who’s been with the Unit for 14 years and will retire in May. We asked her what she’s #ProudestOf from her time working on innovative cancer trials. Thank you for everything, Lou — and happy retirement! 🎉

A card with a quote from Louise, it reads "Over my 14 years here, I’ve been lucky enough to work on some fantastic innovative trials such as FOCUS4 and the STAMPEDE 1 and 2 trials, but I think my proudest achievement is completing the PROMIS study, which transformed the diagnostic pathway for men with suspected prostate cancer. It was a challenging study, involving complex blinding arrangements for the diagnostic tests, but we pulled it off, and it became the primary source of evidence used by NICE to introduce MRI scans into the diagnostic pathway. This now spares many men unnecessary biopsies and treatments. I will be retiring in May, and I feel so grateful for the opportunity to work on such varied and innovative studies with so many fabulous people. Keep up the great work!"

100